Journal of Cancer Research and Clinical Oncology最新文献

{"title":"Psychosocial distress, perceived need and utilization of psycho- social support services in patients in the early phase after the first cancer diagnosis.","authors":"Hannah Zingler, Diana Steinmann, Jochen Ernst, Ute Goerling, Myriel Hermann, Beate Hornemann, Anja Mehnert-Theuerkauf, Tanja Zimmermann","doi":"10.1007/s00432-025-06107-y","DOIUrl":"10.1007/s00432-025-06107-y","url":null,"abstract":"<p><strong>Purpose: </strong>Due to the growing number of new oncological diagnosis and the accompanying psychosocial burden, needs-based psycho-oncological care is important. Adequate planning of psycho-oncological support services is therefore becoming increasingly important. In order to better implement psycho-oncological support services, we investigate psychosocial distress, perceived need and utilization of psycho-oncological support offers in newly diagnosed cancer patients.</p><p><strong>Methods: </strong>Based on a multicenter prospective study, we assessed the cross-sectional data on psychosocial distress, perceived need and utilization of psycho- social support in patients with different tumor entities within 2 months after initial diagnosis. Psychosocial distress was assessed using the Distress Thermometer (DT).</p><p><strong>Results: </strong>Of 1,003 eligible patients who completed the questionnaire (53.0% men, mean age 60.3 years) 39.7% (n = 390) showed above-threshold psychosocial stress (DT: scores ≥ 5) and 21% (n = 207) indicated a perceived need for psycho- social support. 13.5% (n = 136) showed both, psychosocial distress and perceived need for psycho- social support. 15.2% (n = 150) out of all participating patients used psycho-oncology service, 60.7% (n = 597) were willing to accept such an offer. Women were significantly more likely to be psychosocially distressed and to express a need for support. They were also significantly more likely to seek and be willing to accept psycho- social support.</p><p><strong>Conclusion: </strong>Although most patients would accept a psycho- social service, regardless of whether there is psychosocial distress or a need is perceived, the actual utilization was relatively low. It can therefore be assumed that barriers, e.g. structural or personal ones, prevent access. These should be investigated in more detail in future studies.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 2","pages":"65"},"PeriodicalIF":2.7,"publicationDate":"2025-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11802609/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143255715","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Retraction Note: Single-cell omics and machine learning integration to develop a polyamine metabolism-based risk score model in breast cancer patients.","authors":"Xiliang Zhang, Hanjie Guo, Xiaolong Li, Wei Tao, Xiaoqing Ma, Yuxing Zhang, Weidong Xiao","doi":"10.1007/s00432-025-06128-7","DOIUrl":"10.1007/s00432-025-06128-7","url":null,"abstract":"","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 2","pages":"64"},"PeriodicalIF":2.7,"publicationDate":"2025-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11802691/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143255729","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Retraction Note: A prospective diagnostic model for breast cancer utilizing machine learning to examine the molecular immune infiltrate in HSPB6.","authors":"Lizhe Wang, Yu Wang, Yueyang Li, Li Zhou, Sihan Liu, Yongyi Cao, Yuzhi Li, Shenting Liu, Jiahui Du, Jin Wang, Ting Zhu","doi":"10.1007/s00432-025-06130-z","DOIUrl":"10.1007/s00432-025-06130-z","url":null,"abstract":"","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 2","pages":"63"},"PeriodicalIF":2.7,"publicationDate":"2025-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11802608/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143255720","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Small cell lung cancer with EML4-ALK fusion: report of a case responding to ALK TKI and literature review.","authors":"Mingyue Wang, Hongzhi Liu, Ruixin Zhang, Runyu Li, Xiaoyu Qin, Fangling Ning, Lijun Tian","doi":"10.1007/s00432-025-06091-3","DOIUrl":"10.1007/s00432-025-06091-3","url":null,"abstract":"<p><strong>Purpose: </strong>With the continuous development and progress of next-generation gene sequencing technology, many types of anaplastic lymphoma kinase (ALK) rearrangement have been discovered. However, in small cell lung cancer (SCLC), ALK rearrangement is extremely rare and there is no standard treatment protocol. By reviewing the literature, we summarized the previously reported cases of ALK-positive SCLC, and discussed the significance of molecular detection.</p><p><strong>Method: </strong>We report a rare patient with EML4-ALK fusion gene SCLC, a 41-year-old woman with no history of smoking or drinking, who was admitted to the hospital with chest tightness, dyspnea, and cough and sputum. Extensive SCLC (cT4N0M1) was diagnosed after relevant examination and pathological examination. The patient relapsed again six months after receiving first-line chemoradiotherapy. And the patient still developed disease progression (PD) after continued multi-line treatment including chemotherapy, immunotherapy, and anti-vascular therapy. ALK inhibitor is currently being taken orally, and significant clinical response has been achieved. Progression-free survival (PFS) was more than 8 months.</p><p><strong>Result: </strong>ALK rearrangement of SCLC is rare. The stage IV patient with ALK rearrangement benefit from ALK inhibitors after multiline therapy.</p><p><strong>Conclusion: </strong>For patients with ALK-positive SCLC, ALK inhibitors may be a reliable treatment option.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 2","pages":"62"},"PeriodicalIF":2.7,"publicationDate":"2025-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11799027/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143255735","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The impact of PD-L1 polymorphisms on the efficacy of immune checkpoint inhibitors depends on the tumor proportion score: a retrospective study.","authors":"Keiichiro Suminaga, Takashi Nomizo, Hironori Yoshida, Hiroaki Ozasa","doi":"10.1007/s00432-024-06081-x","DOIUrl":"10.1007/s00432-024-06081-x","url":null,"abstract":"<p><strong>Purpose: </strong>This study aims to clarify the relationship between rs2282055, a single-nucleotide polymorphism (SNP) in programmed death-ligand 1 (PD-L1), and TPS. Polcaro et al. (2024) showed that rs822336, a SNP in PD-L1, predicts the effect of immune checkpoint inhibitors (ICIs). However, the study did not show a relationship between rs822336 and the tumor proportion score (TPS), which is currently used as a primary marker. Therefore, we examined this relationship.</p><p><strong>Method: </strong>Patients treated with immune checkpoint inhibitor monotherapy for non-small cell lung cancer at Kyoto University Hospital until January 2023, with TPS data and biological specimens available for SNP measurement, were eligible for this study. Genomic DNA was extracted from peripheral blood leukocytes. We used rs2282055, which is in linkage disequilibrium with rs822336, instead of rs822336, because of its distribution in the Asian patient population. We retrospectively extracted data on age, sex, smoking history, driver mutations, TPS, progression-free survival (PFS), and best response to ICI from medical records.</p><p><strong>Result: </strong>The rs2282055 T/T genotype was associated with significantly better PFS in the TPS-negative population than in the other genotypes. In contrast, no differences were observed in TPS-positive patients.</p><p><strong>Conclusion: </strong>The rs2282055 genotype may help in selecting cases from the TPS-negative patient population that may benefit from ICI therapy.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 2","pages":"61"},"PeriodicalIF":2.7,"publicationDate":"2025-02-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11794342/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143189518","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Deep learning and radiomics for gastric cancer serosal invasion: automated segmentation and multi-machine learning from two centers.","authors":"Hui Shang, Tao Feng, Dong Han, Fengying Liang, Bin Zhao, Lihang Xu, Zhendong Cao","doi":"10.1007/s00432-025-06117-w","DOIUrl":"10.1007/s00432-025-06117-w","url":null,"abstract":"<p><strong>Objective: </strong>The objective of this study is to develop an automated method for segmenting spleen computed tomography (CT) images using a deep learning model. This approach is intended to address the limitations of manual segmentation, which is known to be susceptible to inter-observer variability. Subsequently, a prediction model of gastric cancer (GC) serosal invasion was constructed in conjunction with radiomics and deep learning features, and a nomogram was generated to explore the clinical guiding significance.</p><p><strong>Methods: </strong>This study enrolled 311 patients from two centers with pathologically confirmed of GC. we employed a deep learning model, U-Mamba, to obtain fully automatic segmentation of the spleen CT images. Subsequently, radiomics features and deep learning features were extracted from the entire spleen CT images, and significant features were identified through dimensionality reduction. The clinical features, radiomic features, and deep learning features were organized and integrated, and five machine learning methods were employed to develop 15 predictive models. Ultimately, the model exhibiting superior performance was presented in the form of a nomogram.</p><p><strong>Results: </strong>A total of 18 radiomics features, 30 deep learning features, and 1 clinical features were deemed valuable. The DLRA model demonstrated superior discriminative capacity relative to other models. A nomogram was constructed based on the logistic clinical model to facilitate the usage and verification of the clinical model.</p><p><strong>Conclusion: </strong>Radiomics and deep learning features derived from automated spleen segmentation to construct a nomogram demonstrate efficacy in predicting serosal invasion in GC. Concurrently, fully automated segmentation provides a novel and reproducible approach for radiomics research.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 2","pages":"60"},"PeriodicalIF":2.7,"publicationDate":"2025-02-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11790706/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143122830","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sex-specific differences in recurrence and progression following cytostatic intravesical chemotherapy for non-muscle invasive urothelial bladder cancer (NMIBC).","authors":"Laila Schneidewind, Bernhard Kiss, Thomas Neumann, Jennifer Kranz, Friedemann Zengerling, Sebastian Graf, Annabel Graser, Annemarie Uhlig","doi":"10.1007/s00432-025-06108-x","DOIUrl":"10.1007/s00432-025-06108-x","url":null,"abstract":"<p><strong>Purpose: </strong>To systematically analyze gender-specific differences in recurrence-free survival (RFS), progression-free survival (PFS), cancer-specific survival (CSS), and overall survival (OS) as well as adverse events and quality of Life (QoL) as secondary aims in NMIBC patients undergoing cytostatic intravesical chemotherapy.</p><p><strong>Methods: </strong>A systematic review and meta-analysis were conducted on studies published between 1976 and 2024, following PRISMA guidelines. MEDLINE, Embase and Cochrane Library were used as literature sources. No restrictions were made concerning language, study region or publication type. Data from 12 studies encompassing 1,527 patients were analyzed. Outcomes were assessed using random-effects models, with gender as a primary variable of interest. A risk of bias assessment was done using the ROBINS-I tool or RoB2 as appropriate.</p><p><strong>Results: </strong>The pooled analysis demonstrated no statistically significant gender-specific differences in RFS (HR = 1.0625, 95% CI 0.8094-1.0526) or PFS (HR = 1.0861, 95% CI 0.7038-1.6760). Data on CSS and OS were insufficient for meaningful conclusions. Two included studies analyzed in univariate or multivariate regression gender as risk factor for recurrence or progression, but gender was not a significant risk factor. Adverse events and QoL outcomes were notably underreported, with no gender-specific data available.</p><p><strong>Conclusions: </strong>While this study found no significant gender-based differences in NMIBC outcomes following intravesical chemotherapy, the findings are limited by the small number of studies, underrepresentation of women, and inconsistent reporting of critical outcomes. Future research should prioritize gender-focused analyses and explore the molecular and genetic basis of potential differences to inform precision medicine and equitable care.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 2","pages":"59"},"PeriodicalIF":2.7,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11787168/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143073719","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Biomarker microRNA-371a-3p - expression in malignancies other than germ-cell tumours.","authors":"Gazanfer Belge, Markus Klemke, Bendix Hansen, Cansu Dumlupinar, Aylin Igde, Dirk Arnold, Hans Salwender, Christian Wülfing, Armin Soave, Klaus-Peter Dieckmann","doi":"10.1007/s00432-025-06101-4","DOIUrl":"10.1007/s00432-025-06101-4","url":null,"abstract":"<p><strong>Purpose: </strong>microRNA-371a-3p (M371) is considered a highly sensitive and specific serum biomarker of testicular germ cell tumours (GCTs). However, little is known about the expression of M371 in nontesticular malignancies (NTMs), so far. As knowledge about the expression of the marker in other malignancies is a prerequisite for the clinical application of the test we aimed to explore the M371 expression in other cancers.</p><p><strong>Methods: </strong>M371 serum levels were measured in 137 patients with NTM of 12 different neoplastic entities using the IVDR-certified M371-Test for quantitative real-time PCR. Median M371 serum levels and percentages of M371 level elevations were calculated for the entire NTM group and for entity-specific subgroups. The results were compared with GCT patients (n = 20) and with tumour-free male controls (n = 20) using descriptive statistical methods.</p><p><strong>Results: </strong>Eight patients with NTMs had M371 serum level elevations, corresponding to a false-positive rate (FPR) of 5.84% (95% confidence intervals (CIs) 2.55-11.18%). Expression rates in GCTs and controls were 100% and zero, respectively. Thus, the specificity of the M371-Test for GCT is 94.90% (95% CI 90.21-97.77%) when all NTMs and tumour-free controls are considered. Remarkably, three out of 5 patients with multiple myeloma had elevated M371 levels.</p><p><strong>Conclusion: </strong>The false-positive rate of the M371-Test in other malignancies than GCT is very low, and almost identical with that in healthy males, corresponding to a high specificity of 94.9% for detection of GCT. The surprising finding of M371 elevations in patients with multiple myeloma needs further investigation.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 2","pages":"58"},"PeriodicalIF":2.7,"publicationDate":"2025-01-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11785664/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143065838","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Individual management and prognostic assessment for long-term outcomes using a novel classification system of craniopharyngiomas: a retrospective study of single institution.","authors":"Sen Zhang, Bo Xie, Yi He, Xingshu Zhang, Gu Gong, Mingrui Li, Yinhua Chen, Guodong Tang, Chi Zhang, Chaoying Qin, Qing Liu","doi":"10.1007/s00432-025-06104-1","DOIUrl":"10.1007/s00432-025-06104-1","url":null,"abstract":"<p><strong>Purpose: </strong>This study aims to propose a classification system to more accurately understand the features and nature of different CPs, to investigate the correlation between different topographies of CPs and their surgical outcomes.</p><p><strong>Methods: </strong>A retrospective analysis was conducted on 91 surgically resected CPs. They were categorized into six types based on their location and origin. Simultaneously, the patients were divided into four categories based on the degree of pituitary stalk(PS) preservation postoperatively. Statistical analysis was performed to compare the variables among the different tumor type groups.</p><p><strong>Results: </strong>A total of 91 patients were included. The follow-up data for 59 cases were complete. Tumor volume varied significantly, with the suprasellar-third ventricle type II and ectopic type exhibiting larger volumes (P < 0.05). The choice of surgical approach differed significantly. The recurrence rates were significantly lower for the intrasellar-suprasellar type, suprasellar-third ventricle type II, and third ventricle type (P < 0.05). Patients with intra-stalk tumor growing pattern have a lower degree of PS preservation than those with peri-stalk pattern (P < 0.05). Patients' BMI after surgery was generally higher than before, and the incidence of pituitary dysfunction increased significantly. The proportion of long-term endocrine dysfunction was significantly higher in patients with complete disconnection of PS compared to those with preservation of the PS(P < 0.05).</p><p><strong>Conclusions: </strong>This system holds significant importance in foretelling the rates of recurrence, alterations in postoperative body weight, long-term endocrine status, and potential complications. Furthermore, this study identified preoperative pituitary function status and specific surgical approaches as potential protective factors.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 2","pages":"57"},"PeriodicalIF":2.7,"publicationDate":"2025-01-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11785668/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143065842","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessing the diagnostic potential of SATB2 and β-catenin as biomarkers and therapeutic targets in pancreatic ductal adenocarcinoma.","authors":"Noha Said Helal, Sara Maher, Safia Samir, Hesham A Elmeligy, Mohammed A Aboul-Ezz, Tarek Aboushousha, Mona Moussa","doi":"10.1007/s00432-024-06055-z","DOIUrl":"10.1007/s00432-024-06055-z","url":null,"abstract":"<p><strong>Introduction: </strong>Pancreatic ductal adenocarcinoma (PDAC) is associated with poor prognosis. The roles of the transcription factor special AT-rich binding protein-2 (SATB2) and β-catenin in PDAC have been a subject of controversy. We aimed to assess the diagnostic and prognostic impact of SATB2 and β-catenin in PDAC.</p><p><strong>Methods: </strong>We analyzed 44 paraffin-embedded tissue blocks along with corresponding blood and pancreatic tissues. We evaluated SATB2 expression using immunohistochemistry (IHC) and enzyme-linked immunosorbent assay (ELISA). β-catenin was assessed using IHC and real-time polymerase chain reaction (qPCR).</p><p><strong>Results: </strong>High SATB2 expression and low β-catenin expression were associated with a poor prognosis in PDAC, including advanced pathological tumor stage (pT-stage), pathological lymph node stage (pN-stage), and TNM stage. We found a positive correlation between SATB2 expression assessed by IHC and the concentration of SATB2 in both serum and tissue samples measured by ELISA. We observed a positive correlation between β-catenin expression assessed by IHC and β-catenin levels measured by qPCR.</p><p><strong>Conclusions: </strong>SATB2 and β-catenin could provide valuable insights into the development of pancreatic cancer, and targeting them may be beneficial for the prevention and treatment of PDAC. The levels of SATB2 in serum show promise for the diagnosis and tumor invasion of pancreatic cancer.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 2","pages":"56"},"PeriodicalIF":2.7,"publicationDate":"2025-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11779791/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143059239","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}